Introduction {#sec1-1}
============

Asthma is one of the most common chronic diseases. An estimated 300 million people worldwide suffer from asthma, with 250,000 annual deaths attributed to the disease.\[[@ref1]\] The prevalence of asthma in different countries varies widely, but the disparity is narrowing due to rising prevalence in low- and middle-income countries and plateauing in high-income countries.\[[@ref2]\] Increased rate of its prevalence may be because of changes in life-style, rapid industrialization, increase in air pollution etc. Common risk factors of asthma include exposure to allergens (such as those for work place, house dust, mites, animal fur, cockroaches, pollens, and mold), occupational irritants,\[[@ref1]\] tobacco smoke,\[[@ref3]\] respiratory infections, food allergies (such as milk, peanuts, and eggs), and psychological stress.\[[@ref4]\] During asthma attack, the lining of the bronchial tubes swell, causing the airways to narrow and reducing the flow of air into and out of the lungs causing sleeplessness, daytime fatigue, reduced activity levels and school and work absenteeism.\[[@ref5]\] This miserable condition is comparable to *Tamaka Shwasa* in Ayurveda.

Detailed description of *Tamaka Shwasa* including pathogenesis, signs and symptoms, and treatment is available in Ayurveda classics.\[[@ref6]\] The symptoms of *Tamaka Shwasa* are *Asinolabhate Soukhyam* (comfortable in sitting posture), *Pratamyati Vegataha* (tachypnea), *Kasa* (cough), *Kanthodhwansa* (hoarseness of voice), *Parshwa Graham* (stiffness in flanks), etc., and are similar to the symptoms of bronchial asthma. Although modern system of medicine has their own lines of treatment for this condition, they are known to develop various adverse reactions. Observing all these, the scenario is hopefully looking toward traditional systems of medicine such as Ayurveda for better answers.

*Vasa Avaleha* (VA) is herbal formulation used commonly in the treatment of various diseases of respiratory system.\[[@ref7]\] In the current study, it has been planned to evaluate comparative clinical efficacy of VA and its granules (GVA) in *Tamaka Shwasa*.

Materials and Methods {#sec1-2}
=====================

Patients of both sex, between the age of 12 and 70 years with mild persistent cases of bronchial asthma, were registered in the trial from outdoor and indoor patient department IPGT and RA Hospital, Jamnagar. The study obtained Institutional Ethics Committee clearance (PGT/7-A/2012-2013/1964/22 dated 21/09/2012) and registered at Clinical Trial Registry of India (CTRI/2012/12/003184). A written informed consent from each patient was taken before enrolling in the clinical trial.

Exclusion criteria {#sec2-1}
------------------

Dyspnea resulting from other diseases such as left ventricular failure, chronic obstructive pulmonary disease (chronic bronchitis, emphysema), upper respiratory tract obstruction, patients with anemia, pneumonia, tuberculosis, lung cancer, lung abscess, and other such complicated conditions were excluded from the study.

Investigations {#sec2-2}
--------------

Routine hematological, especially white blood cell, erythrocyte sedimentation rate, absolute eosinophil count (AEC), and urine examination were carried out in all the patients. Biochemical investigations such as random blood sugar, serum glutamic pyruvic transaminase, serum glutamic oxaloacetic transaminase, and chest X-ray were carried out as per the need to exclude other pathologies. Breath holding time (BHT) and peak expiratory flow rate (PEFR) were also recorded in all the patients before and after treatment.

Diet and restrictions {#sec2-3}
---------------------

Patients were advised to avoid cause and aggravating factors such as curd, cold drinks, fish and meat, tobacco chewing and smoking, alcohol, excessive physical work, day sleep, and exposure to dust, smoke, pets, and pollens. Patients were advised to use lukewarm water after meal and at bed time. They were also advised for light diet, breathing exercises such as *Pranayama*, use of mask while working, to avoid exposure to dust and smoke, etc.

Trial drugs {#sec2-4}
-----------

The raw material was procured from Pharmacy, Gujarat Ayurved University, Jamnagar and authenticated in the Pharmacognosy Laboratory, IPGT and RA, Jamnagar. Both trial drugs were prepared in the Department of Rasashastra and Bhaishajya Kalpana, IPGT and RA, Jamnagar by following classical guidelines. Formulation composition of both trial drugs that is VA and GVA is shown in [Table 1](#T1){ref-type="table"}.

###### 

Formulation composition of *Vasa Avaleha* and Granules of *Vasa Avaleha*

![](AYU-36-271-g001)

Grouping and posology {#sec2-5}
---------------------

A total of 66 patients were randomly grouped into A and B using computer generated randomization \[[Chart 1](#F1){ref-type="fig"}\], Group A (*n* = 32) received VA, while Group B (*n* = 34) received GVA at dose of 6 g twice a day with lukewarm water in the morning and evening for the duration of 28 days. Follow-up period was 14 days in both groups.

![CONSORT flow diagram](AYU-36-271-g002){#F1}

Criteria for assessment {#sec2-6}
-----------------------

Efficacy of the trial drugs was analyzed by specific grading pattern including asthma control questionnaire (ACQ) and asthma control test (ACT)\[[@ref8][@ref9][@ref10]\] in terms of relief observed in cardinal signs and symptoms before and after treatment. Changes in PEFR, BHT, and AEC were also considered in evaluating comparative efficacy of the trial drugs.

Statistical analysis {#sec2-7}
--------------------

Obtained data were statistically analyzed using Wilcoxon signed rank test, Paired *t*-test, Unpaired *t*-test, and Chi-square test.

Observations and Results {#sec1-3}
========================

It was observed that 51.51% patients were of *Vata-Kapha Prakriti* followed by *Vata-Pitta Prakriti* (30.30%) and *Pitta-Kapha Prakriti* (18.18%). About 7.57% of patients registered in the study were addicted to tobacco smoking. Chronicity of 1--5 years duration was reported in 33.33% patients.

Effect of therapy on cardinal symptoms {#sec2-8}
--------------------------------------

Statistically highly significant results were observed in all the cardinal symptoms. Group A showed better improvement than Group B in breathlessness, frequency and intensity of attack and cough whereas in Group B, better effect on duration of attack, wheezing, tachypnea and night symptoms was found \[[Table 2](#T2){ref-type="table"}\]. The difference between the groups was statistically insignificant \[[Table 3](#T3){ref-type="table"}\].

###### 

Effect of *Vasa Avaleha* and Granules of *Vasa Avaleha* on chief complaints
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###### 

Effect of test drugs Group A on chief complaints in comparison to Group B
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Effect of therapy on associated symptoms {#sec2-9}
----------------------------------------

Effect of both trail drugs on associated symptoms was also highly significant except dryness of oral cavity in Group B \[[Table 4](#T4){ref-type="table"}\].

###### 

Effect of *Vasa Avaleha* and Granules of *Vasa Avaleha* drugs on associated symptoms
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Effect of therapy on objective parameters {#sec2-10}
-----------------------------------------

Effect of both trail drugs on objective parameters such as need of any reliever, BHT, and PEFR was statistically highly significant \[[Table 5](#T5){ref-type="table"}\]. ACT showed highly significant results in both groups whereas ACQ showed significant results in both groups \[[Table 6](#T6){ref-type="table"}\].

###### 

Effect of *Vasa Avaleha* and granules of *Vasa Avaleha* on objective criteria
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###### 

Effect of *Vasa Avaleha* and granules of *Vasa Avaleha* on asthma control test and asthma control questionnaire
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Overall effect of therapy {#sec2-11}
-------------------------

Complete remission was not found with any of the drugs. At the end of treatment, moderate improvement was found in 25.93% patients in Group A while 32.26% in Group B; mild improvement was found in 66.67% in Group A while 64.52% in Group B.

Discussion {#sec1-4}
==========

Ayurveda emphasizes on *Srotorodha* (obstruction of channels) in the manifestation of *Shwasa Roga*, which is the resultant of disturbance in the equilibrium of *Vata* and *Kapha*. Hence, drugs that are beneficial in removing the obstruction and maintain the physiological equilibrium of *Vata* and *Kapha* are useful in pacifying *Tamaka Shwasa*. *Acharyas* have also provided specific guidelines in the management of *Tamaka Shwasa* with drugs having *Vata-Kapha Hara*, *Ushna*, and *Vatanulomana* properties.\[[@ref11]\]

VA, an herbal formulation indicated in respiratory diseases, acts on the disease by *Vata-Kaphaghna* property. *Sukshma* and *Tikshna Guna* of *Vasa* (*Adhatoda vasica* Nees.), *Pippali* (*Piper longum* Linn.), *Madhu* (honey) help in *Kaphanihsarana* and remove *Upalepa* of *Kapha* in *Kantha* (throat) and *Ura* (chest). *Vatahara* drugs such as *Sita*, *Go-Ghrita* (cow ghee), *Pippali* cause *Vatanulomana* and passify *Vimarga Kupita Vata* caused due to *Vimargagami Prana* and *Apana Vayu*. *Go-Ghrita*, *Pippali* also act on *Pitta Sthana* improving the function of *Agni* thus normalizing *Vatakarma*. This process sets right the digestion, assimilation, and metabolism. Further, *Go-Ghrita*\[[@ref12]\] and *Pippali* help in improving immunity of the body with their *Rasayana* (rejuvinative) effect, thus preventing the recurrences of symptoms.

*Vasa*, a major component of VA, is indicated in diseases such as *Shwasa*, *Rajayakshma* (tuberculosis), *Raktapitta*, *Shotha* (edema), and *Jwara* (fever).\[[@ref13]\] Vasicine and vasicinone, the bitter alkaloids available in the plant, has bronco-dilatory effect. Few studies have proven 6--10 times greater efficacy of vasicinone against aminophylline in cases of bronchial asthma.\[[@ref14]\]

*Pippali* enhances bioavailability,\[[@ref15]\] which helps in maintaining the major therapeutic principles in the systemic circulation for longer duration that is responsible for the anti-asthmatic activity of the formulation.

Statistically highly significant (*P* \< 0.001) results were obtained in both groups on cardinal symptoms such as breathlessness, paroxysm of breathlessness, intensity of the attack, frequency of attack, cough, nasal symptoms, pain in ribs, night symptoms, and immediate relief after expectoration. However, the percentage change was more in Group A. Whereas in symptoms such as duration of attack, wheezing, tachypnea and night symptoms, more percentage change was found in Group B. Statistically insignificant difference was found on cardinal symptoms and vital parameters in between the groups.

Effect of both trail drugs shows highly significant result in comfort in sitting and desire on warmness. Significant result was observed in sweating on forehead and dryness in oral cavity (Group A), whereas in Group B, insignificant result was observed in dryness of oral cavity.

The usage of trial drugs, the duration, frequency, and dosage of the emergency allopathic medicines including steroids were significantly reduced and in few cases, they were withdrawn. Vital parameters in both groups treated patients shown highly significant reduction in respiratory rate and highly significant increase was found in BHT and PEFR. Effect of therapy on ACT and ACQ shows highly significant results in both treated groups. Most of the patients in their follow-up too did not felt the need of any emergency medication.

Conclusions {#sec1-5}
===========

The current study revealed that both trial drugs are effective in the treatment of *Tamaka Shwasa* without manifesting any adverse reactions. Use of modern medicines was also curtailed or withdrawn during the treatment with increased quality of life. Hence, safety can be added as a couplet to the conventional anti-asthmatic drugs.
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